The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1121

I look at this in a positive way. We are about AUD$20M away from being in a position to go to complete trial, negotiate whatever and go to market.
We get the money and we can do this in a relatively short time-frame assuming the results being seen continue.
We know we need the money but we also know the data is very much supporting the hypothesis that Monepantel is working on Neurological diseases.
It is not being kept a secret either, the market knows we don't have enough cash to foot the bills for this right now.

Michael has been busy working the crowd so we don't have a clue precisely how this is going to be covered. He has a plan and none of us know it nor should we right now.

It is potentially a combination of sources including grants, discounts on costs, placements, loans, conversion of options...... I really don't know.

(loans repaid by calculated tax rebates, up and coming grants etc)

What i do know is, money makes things happen and that AUD$20M, in the greater scheme of things, is a small price to pay to be able to move forward unimpeded by cash.

adreamer